T2 Biosystems Story 

TTOO  USA Stock  USD 1.95 0.08 3.94% 
By Vlad Skutelnik  Macroaxis Story 
66% of stocks are less volatile than T2 Biosystems, and 68% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Since many greedy investors are excited about healthcare space, let's outline T2 Biosystems against its current volatility. We will evaluate if T2 Biosystems' current volatility will continue into March.
T2 Biosystems currently holds 48.27 M in liabilities with Debt to Equity (D/E) ratio of 2.75, implying the company greatly relies on financing operations through barrowing. This firm has a current ratio of 4.87, suggesting that it is liquid enough and is able to pay its financial obligations when due. T2 Biosystems holds a performance score of 16 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of 1.3662, which indicates a somewhat significant risk relative to the market. Let's try to break down what T2 Biosystems's beta means in this case. As returns on the market increase, returns on owning T2 Biosystems are expected to decrease by larger amounts. On the other hand, during market turmoil, T2 Biosystems is expected to outperform it. Although it is essential to pay attention to T2 Biosystems existing price patterns, it is also good to be reasonable about what you can do with equity price patterns. Our way in which we are measuring future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if T2 Biosystems expected return of 1.83 will be sustainable into the future, we have found twentyseven different technical indicators, which can help you to check if the expected returns are sustainable. Use T2 Biosystems value at risk, and the relationship between the information ratio and kurtosis to analyze future returns on T2 Biosystems.
Volatility is a rate at which the price of T2 Biosystems or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of T2 Biosystems may increase or decrease. In other words, similar to T2 Biosystems's beta indicator, it measures the risk of T2 Biosystems and helps estimate the fluctuations that may happen in a short period of time. So if prices of T2 Biosystems fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.How important is T2 Biosystems's Liquidity
T2 Biosystems financial leverage refers to using borrowed capital as a funding source to finance T2 Biosystems CS ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. T2 Biosystems financial leverage is typically calculated by taking the company's all interestbearing debt and dividing it by total capital. So the higher the debttocapital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between T2 Biosystems's total debt and its cash.
How T2 Biosystems utilizes its cash?
To perform a cash flow analysis of T2 Biosystems, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash T2 Biosystems is receiving and how much cash it distributes out in a given period. The T2 Biosystems cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
T2 Biosystems Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (56.28 Million)